[Rivaroxaban versus warfarin in high-risk patients with antiphospholipid syndrome]

Z Rheumatol. 2019 Aug;78(6):550-551. doi: 10.1007/s00393-019-0659-y.
[Article in German]
No abstract available

MeSH terms

  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome* / drug therapy
  • Humans
  • Rivaroxaban* / therapeutic use
  • Warfarin* / therapeutic use

Substances

  • Anticoagulants
  • Warfarin
  • Rivaroxaban